Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | acetylcholinesterase | 0.903 | 1 | 1 |
Echinococcus multilocularis | acetylcholinesterase | 0.903 | 1 | 1 |
Mycobacterium tuberculosis | POSSIBLE PARA-NITROBENZYL ESTERASE (FRAGMENT) | 0.1526 | 0 | 0.5 |
Onchocerca volvulus | 0.1526 | 0 | 0.5 | |
Loa Loa (eye worm) | acetylcholinesterase 1 | 0.903 | 1 | 1 |
Onchocerca volvulus | 0.1526 | 0 | 0.5 | |
Onchocerca volvulus | 0.1526 | 0 | 0.5 | |
Onchocerca volvulus | 0.1526 | 0 | 0.5 | |
Schistosoma mansoni | family S9 non-peptidase homologue (S09 family) | 0.903 | 1 | 1 |
Mycobacterium tuberculosis | POSSIBLE PARA-NITROBENZYL ESTERASE (FRAGMENT) | 0.1526 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.903 | 1 | 1 |
Echinococcus granulosus | carboxylesterase 5A | 0.903 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.903 | 1 | 1 |
Echinococcus multilocularis | carboxylesterase 5A | 0.903 | 1 | 1 |
Mycobacterium tuberculosis | Carboxylesterase LipT | 0.1526 | 0 | 0.5 |
Trichomonas vaginalis | spcc417.12 protein, putative | 0.1526 | 0 | 0.5 |
Echinococcus granulosus | acetylcholinesterase | 0.903 | 1 | 1 |
Echinococcus multilocularis | acetylcholinesterase | 0.903 | 1 | 1 |
Trichomonas vaginalis | carboxylesterase domain containing protein, putative | 0.1526 | 0 | 0.5 |
Brugia malayi | Carboxylesterase family protein | 0.903 | 1 | 1 |
Onchocerca volvulus | 0.1526 | 0 | 0.5 | |
Mycobacterium ulcerans | carboxylesterase, LipT | 0.1526 | 0 | 0.5 |
Loa Loa (eye worm) | carboxylesterase | 0.903 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
CC50 (ADMET) | = 19937 nM | Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay | ChEMBL. | 24769348 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.